Recent Company News

• 09:26 AM ET Dec 30, 2025
  

  Akari Therapeutics provides catalyst and milestone update in shareholder letter ($0.26, 0.00)

• 08:32 AM ET Dec 23, 2025
  

  Akari Therapeutics initiates GMP manufacturing of AKTX-101 program ($0.26, 0.00)

• 09:31 AM ET Dec 16, 2025
  

  Akari Therapeutics announces $5M financing, including concurrent registered direct offering and private placement priced at-market ($0.41, 0.00)

• 08:42 AM ET Dec 09, 2025
  

  Akari Therapeutics announces preclinical data for AKTX-101 ($0.34, 0.00)

• 12:37 PM ET Nov 18, 2025
  

  Transcript Intelligence: Akari Therapeutics at Society for Immunotherapy of Cancer Meeting ($0.48, +0.01)

• 05:05 PM ET Nov 13, 2025
  

  Akari Therapeutics reports Q3 GAAP EPS ($0.00) vs year-ago ($0.00) - 10-Q ($0.52, 0.00)

• 08:37 AM ET Nov 10, 2025
  

  Akari Therapeutics announces presentation of immune mechanism-of-action data for novel ADC payload PH1 ($0.64, 0.00)

• 09:16 AM ET Nov 05, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:24 AM ET Nov 05, 2025
  

  StreetAccount Summary - US Pre-market trading

• 09:29 AM ET Nov 04, 2025
  

  Akari Therapeutics announces abstract highlighting immune mechanism-of-action data for PH1 ($0.73, 0.00)